Obesity and Familial Predisposition Are Significant Determining Factors of an Adverse Metabolic Profile in Young Patients with Congenital Adrenal Hyperplasia

Autor(es)

Moreira, Ricardo P. P. ^[1] ; Villares, Sandra M. ^[2] ; Madureira, Guiomar ^[1] ; Mendonca, Berenice B. ^[1] ; Bachega, Tania A. S. S. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Unidade Endocrinol Desenvolvimento, Lab Hormonios & Genet Mol LIM 42, Disciplina Endocrinol, Hosp Clin, Fac Med, Sao Paulo - Brazil

^[2] Univ Sao Paulo, Fac Med, Lab Nutr Humana & Doencas Metab LIM 25, Disciplina Endocrinol, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Hormone Research in Paediatrics; v. 80, n. 2, p. 111-118, 2013.
• Citações Web of Science: 10

Resumo

Background/Aims: Glucocorticoid (GC) therapy is known to predispose to an adverse metabolic profile. Therefore, we investigated the prevalence of obesity and metabolic syndrome (MetS) in young patients with congenital adrenal hyperplasia (CAH) and to correlate this prevalence with GC treatment and family history. Methods: The study population consisted of 33 young CAH patients who received cortisone acetate during their growth periods; those who were salt wasters also received fludrocortisone. Obesity was defined by a body mass index (BMI) >95th percentile and MetS by the National Cholesterol Education Program Third Adult Treatment Panel modified criteria. Each patient's familial history of MetS components was assessed. The impact of GC therapy on the metabolic profile was analyzed by comparing CAH patients with BMI z-score-matched controls. Results: MetS and obesity were observed in 12.1 and 30.3% of the CAH patients, respectively, both of which were higher than in the reference population. A positive family history of MetS was found to be more prevalent in the obese patients compared with the nonobese CAH patients, and similar findings were observed for the controls. The metabolic profile did not differ between the CAH patients and matched subjects. Conclusion: CAH patients presented a higher prevalence of obesity and MetS, which were not correlated with the GC treatment. This study suggests that obesity and familial predisposition are significant determining factors for an adverse metabolic profile in CAH patients. Copyright (C) 2013 S. Karger AG, Basel (AU)

• Processo FAPESP: 09/54394-4 - Análise dos fatores genéticos envolvidos no desenvolvimento da síndrome metabólica durante a terapia com glicocorticóide em pacientes portadores da deficiência da 21-hidroxilase
• Beneficiário: Ricardo Paranhos Pires de Moreira
• Linha de fomento: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 09/54238-2 - Análise do efeito modulatório de polimorfismos nos genes CYP3A7, POR e NR3C1 na terapia com glicocorticóide da forma clássica da deficiência da 21-hidroxilase
• Beneficiário: Tania Aparecida Sartori Sanchez Bachega
• Linha de fomento: Auxílio à Pesquisa - Regular